PTC Therapeutics reinstated with hold rating by Truist Securities; target price $62
PTCT•Truist Securities reinstated coverage of PTC Therapeutics with a hold rating and a $62 target price.
Related News
Oil heads for weekly gain with focus on Middle East supply
USO•
Curtiss-Wright Corporation target price cut to $625 from $860
CW•
Bloomin' Brands publishes update to financial calendar
BLMN•
Nasdaq trade halt continues; reason not available at 9:30 a.m.
UCFIW•
Moog Inc: Morgan Stanley raises target price to $448 from $405
MOG-A•